Latent Labs

Latent Labs is a biotechnology company developing foundational artificial intelligence (AI) models to make biology programmable. The company’s mission is to use generative AI to enable control over molecular biology, thereby transforming applications across healthcare and sustainability.

Scope and Technology

Latent Labs focuses on creating frontier generative AI models that capture the fundamental principles of biology. By modeling molecular interactions, the company seeks to shift biology from an observational science to an engineering discipline. Through these models, Latent Labs aims to empower partners to generate new antibodies, optimize enzymes, and advance genetic engineering capabilities.

Latent-X Model

The company’s first frontier model, Latent-X, is an atomic-level AI system for de novo protein binder design.

• Design Features: The model generates binders for both targeted and untargeted proteins from scratch, resolving the geometric challenges of molecular binding at the atomic scale. It produces structures that adhere to biochemical rules, such as hydrogen bondin,g to ensure high affinity and specificity.
• Validation Results: In extensive laboratory testing, Latent-X achieved 91–100% hit rates for macrocycles and picomolar-range binding affinities for mini-binders — exceeding the performance of several previous state-of-the-art models.
• Therapeutic Modalities: The model has successfully designed various binder types, including macrocycles and mini-binders, as potential therapeutic modalities.

Latent Labs Platform

Latent-X is deployed through the Latent Labs Platform, a no-code system that enables users to perform tasks such as target upload, epitope selection, binder design, and computational ranking without programming expertise. This platform extends access to scientists and research teams with limited AI infrastructure, democratizing the use of advanced biological modeling tools.

Corporate Information

Latent Labs was founded in 2023 by Dr. Simon Kohl, who previously co-led the protein design team at Google DeepMind and served as a senior research scientist on the AlphaFold2 project.

In February 2025, the company emerged from stealth with a $50 million funding round co-led by Radical Ventures and Sofinnova Partners. Additional investors include 8VC, Pillar VC, Kindred Capital, Isomer, and Flying Fish Ventures, with angel investors such as Jeff Dean (Chief Scientist, Google) and Dario Amodei (CEO, Anthropic).

Latent Labs operates from London and San Francisco. Its team includes former AlphaFold2 contributors and experts from DeepMind, Microsoft, Google, Stability AI, Exscientia, Mammoth Bio, Altos Labs, and Zymergen.